In vitro evidence for increased cellular immunity to lung cancer antigen during Levamisole immunotherapy

M. M. Urist, A. W. Boddie, Courtney Townsend, E. C. Holmes

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Levamisole, a potentiator of cell-mediated immunity, has been reported to increase survival in patients with resectable carcinoma of the lung. Cell-mediated immunity can be measured in vitro by the leukocyte migration inhibition test. We have previously reported that this test detects cell-mediated immunity to human lung tumor antigens. In the present studies, patients with lung cancer were treated with Levamisole. Their leukocytes were evaluated in the leukocyte migration inhibition assay before, during, and following Levamisole therapy. Small increases in cell-mediated immunity were observed when patients had a high pre-existing tumor immunity. When tumor-associated reactivity was absent prior to therapy, larger increases were measured. Although Levamisole is a nonspecific immunostimulant, these data indicate that in vitro anti-tumor immune responses are enhanced by Levamisole therapy. Augmentation of cell-mediated immunity to tumor antigens may explain the clinical benefits of Levamisole therapy.

Original languageEnglish (US)
Pages (from-to)189-194
Number of pages6
JournalJournal of Thoracic and Cardiovascular Surgery
Volume73
Issue number2
StatePublished - 1977
Externally publishedYes

Fingerprint

Levamisole
Cellular Immunity
Immunotherapy
Lung Neoplasms
Antigens
Leukocyte Cell Migration Assays
Neoplasm Antigens
Immunologic Adjuvants
Neoplasms
Lung
Therapeutics
In Vitro Techniques
Immunity
Leukocytes
Carcinoma
Survival

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

In vitro evidence for increased cellular immunity to lung cancer antigen during Levamisole immunotherapy. / Urist, M. M.; Boddie, A. W.; Townsend, Courtney; Holmes, E. C.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 73, No. 2, 1977, p. 189-194.

Research output: Contribution to journalArticle

@article{89f8eb1f1da549888808c75740fd0f75,
title = "In vitro evidence for increased cellular immunity to lung cancer antigen during Levamisole immunotherapy",
abstract = "Levamisole, a potentiator of cell-mediated immunity, has been reported to increase survival in patients with resectable carcinoma of the lung. Cell-mediated immunity can be measured in vitro by the leukocyte migration inhibition test. We have previously reported that this test detects cell-mediated immunity to human lung tumor antigens. In the present studies, patients with lung cancer were treated with Levamisole. Their leukocytes were evaluated in the leukocyte migration inhibition assay before, during, and following Levamisole therapy. Small increases in cell-mediated immunity were observed when patients had a high pre-existing tumor immunity. When tumor-associated reactivity was absent prior to therapy, larger increases were measured. Although Levamisole is a nonspecific immunostimulant, these data indicate that in vitro anti-tumor immune responses are enhanced by Levamisole therapy. Augmentation of cell-mediated immunity to tumor antigens may explain the clinical benefits of Levamisole therapy.",
author = "Urist, {M. M.} and Boddie, {A. W.} and Courtney Townsend and Holmes, {E. C.}",
year = "1977",
language = "English (US)",
volume = "73",
pages = "189--194",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - In vitro evidence for increased cellular immunity to lung cancer antigen during Levamisole immunotherapy

AU - Urist, M. M.

AU - Boddie, A. W.

AU - Townsend, Courtney

AU - Holmes, E. C.

PY - 1977

Y1 - 1977

N2 - Levamisole, a potentiator of cell-mediated immunity, has been reported to increase survival in patients with resectable carcinoma of the lung. Cell-mediated immunity can be measured in vitro by the leukocyte migration inhibition test. We have previously reported that this test detects cell-mediated immunity to human lung tumor antigens. In the present studies, patients with lung cancer were treated with Levamisole. Their leukocytes were evaluated in the leukocyte migration inhibition assay before, during, and following Levamisole therapy. Small increases in cell-mediated immunity were observed when patients had a high pre-existing tumor immunity. When tumor-associated reactivity was absent prior to therapy, larger increases were measured. Although Levamisole is a nonspecific immunostimulant, these data indicate that in vitro anti-tumor immune responses are enhanced by Levamisole therapy. Augmentation of cell-mediated immunity to tumor antigens may explain the clinical benefits of Levamisole therapy.

AB - Levamisole, a potentiator of cell-mediated immunity, has been reported to increase survival in patients with resectable carcinoma of the lung. Cell-mediated immunity can be measured in vitro by the leukocyte migration inhibition test. We have previously reported that this test detects cell-mediated immunity to human lung tumor antigens. In the present studies, patients with lung cancer were treated with Levamisole. Their leukocytes were evaluated in the leukocyte migration inhibition assay before, during, and following Levamisole therapy. Small increases in cell-mediated immunity were observed when patients had a high pre-existing tumor immunity. When tumor-associated reactivity was absent prior to therapy, larger increases were measured. Although Levamisole is a nonspecific immunostimulant, these data indicate that in vitro anti-tumor immune responses are enhanced by Levamisole therapy. Augmentation of cell-mediated immunity to tumor antigens may explain the clinical benefits of Levamisole therapy.

UR - http://www.scopus.com/inward/record.url?scp=0017350528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017350528&partnerID=8YFLogxK

M3 - Article

VL - 73

SP - 189

EP - 194

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 2

ER -